Precision Medicine and Next-Generation Sequencing Diagnostic at European Society for Medical Oncology Congress 2022: The Unbreakable Bond
EMJ Oncology · 2022
DOI: 10.33590/emjoncol/10019771 ↗Kurz gefasst
Fachartikel in der Zeitschrift EMJ Oncology, 2022. Verfasst von Chiara Rolando und 1 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
Returning to in-person for the first time since the COVID-19 pandemic started, the European Society for Medical Oncology (ESMO) 2022 conference was packed with new and interesting data.Highlights include updates from DESTINY-Gastric02 and DESTINY-Lung02 exploring treatment with trastuzumab deruxtecan in different settings, and new and encouraging results for the KRAS inhibitors adagrasib and the first-in-class sotorasib in advanced colorectal cancer (CRC) and in previously treated patients with non-small cell lung cancer (NSCLC).Of note, updates from APPLE and INSIGHT2 trials strengthen the application of liquid biopsy for disease monitoring and recurrence, while the PATHFINDER study results opened a fierce debate in the medical community, with many stakeholders suggesting that liquid biopsy is not yet fully ready for prime time in early cancer detection.
Zitieren
APA
Rolando, C., & Quagliata, L. (2022). Precision Medicine and Next-Generation Sequencing Diagnostic at European Society for Medical Oncology Congress 2022: The Unbreakable Bond. EMJ Oncology. https://doi.org/10.33590/emjoncol/10019771
Vancouver
Rolando C, Quagliata L. Precision Medicine and Next-Generation Sequencing Diagnostic at European Society for Medical Oncology Congress 2022: The Unbreakable Bond. EMJ Oncology. 2022. doi:10.33590/emjoncol/10019771
BibTeX
@article{Rolando2022,
author = {Rolando, Chiara and Quagliata, Luca},
title = {Precision Medicine and Next-Generation Sequencing Diagnostic at European Society for Medical Oncology Congress 2022: The Unbreakable Bond},
journal = {EMJ Oncology},
year = {2022},
doi = {10.33590/emjoncol/10019771}
}
EUVIMED